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Fibroblasts located adjacent to the tumor [cancer-associated
ﬁbroblasts (CAFs)] that constitute a large proportion of the
cancer-associated stroma facilitate the transformation process.
In this study, we compared the biological behavior of CAFs that
were isolated from a prostate tumor to their normal-associated
ﬁbroblast (NAF) counterparts. CAFs formed more colonies when
seeded at low cell density, exhibited a higher proliferation rate
and were less prone to contact inhibition. In contrast to the gen-
eral notion that high levels of a-smooth muscle actin serve as
a marker for CAFs, we found that prostate CAFs express it at
a lower level compared with prostate NAFs. Microarray analysis
revealed a set of 161 genes that were altered in CAFs compared
with NAFs. We focused on whey acidic protein four-disulﬁde core
domain 1 (WFDC1), a known secreted protease inhibitor, and
found it to be downregulated in the CAFs. WFDC1 expression
was also dramatically downregulated in highly proliﬁc mesenchy-
mal cells and in various cancers including ﬁbrosarcomas and in
tumors of the lung, bladder and brain. Overexpression of WFDC1
inhibited the growth rate of the ﬁbrosarcoma HT1080 cell line.
Furthermore, WFDC1 level was upregulated in senescent ﬁbro-
blasts. Taken together, our data suggest an important role for
WFDC1 in inhibiting proliferation of both tumors and senescent
cells. Finally, we suggest that the downregulation of WFDC1
might serve as a biomarker for cellular transformation.
Introduction
Prostate cancer is one of the leading cancers diagnosed in men in the
western world (1). Although the vast majority of prostate cancers
stem from the epithelial compartment of the prostate, genetic and
molecular studies indicate that tumorigenesis is not only solely de-
termined by the malignant cancer cells themselves but also by the
tumor stroma. Fibroblasts, that constitute the majority of the stroma,
are elongated cells embedded in the connective tissue and are to
a large extent responsible for its synthesis and maintenance. Fibro-
blasts participate in the regulation of diverse processes such as
inﬂammation, wound healing and differentiation of their neighbor-
ing epithelial cells (2). They synthesize ﬁbrillar extracellular matrix
(ECM) vital proteins, such as type I, III and V collagens and ﬁbro-
nectin. In contrast, ﬁbroblasts are also an important source of ECM-
degrading proteases such as matrix metalloproteinases that stress
their crucial role in maintaining the ECM homeostasis. Recent stud-
ies have established the notion that ﬁbroblasts are prominent modi-
ﬁers of cancer progression, with a speciﬁc subpopulation designated
as cancer-associated ﬁbroblasts (CAFs) that play a key role in pro-
moting tumor initiation and progression. During prostatic carcino-
genesis, periepithelial stroma undergoes progressive loss of smooth
muscle accompanied by the appearance of CAFs, either through
alterations in differentiation programs of smooth muscle cells or
by recruitment of ﬁbroblasts to the tumor site. CAFs isolated from
malignant tissues demonstrate distinct differences from normal-
associated ﬁbroblasts (NAFs), including increased production of
collagens and epithelial growth factors as well as enhanced prolif-
eration rate (3–5). In vivo studies revealed that co-injection of CAFs
derived from prostate adenocarcinoma with normal epithelia enhan-
ces the growth of the latter. Furthermore, co-injection of CAFs and
immortalized epithelial cells results in tumors that surpass the con-
trol (only immortalized epithelia) tumor mass by 500-fold (6).
Recent studies focused on identifying speciﬁc factors that are secreted
by CAFs and potentially accelerate the transformation of neighboring
epithelia. For instance, it was shown that breast cancer-derived CAFs
promote tumor growth and angiogenesis through elevated SDF-1/
CXCL12 secretion (7). Another study revealed that transforming
growth factor-b signaling in ﬁbroblasts modulates the oncogenic po-
tentialofadjacentepithelia(8).Oneof theproteinsthatare knowntobe
secreted from the prostate stroma and inﬂuenceadjacent epithelia is the
whey acidic protein four-disulﬁde core domain 1 (WFDC1) (9). It
belongs to a family of proteins with a so-called ‘whey acidic protein’
domain that are often modulated in cancers (10). Whey acidic proteins
contain at least one whey acidic protein motif consisting of  50 amino
acids with eight highly conserved cysteine residues that form four
disulﬁde bridges. Usually, this motif is characterized by serine protease
inhibitory activity. Four members of this family were suggested as
markers for various cancers: elaﬁn, antileukoproteinase, WFDC2 and
WFDC1 (10). WFDC1 was ﬁrst puriﬁed from urogenital-sinus mesen-
chymalcelllineofaratfetus andwas designated asprostate-speciﬁc20
(ps20). When added to the media, puriﬁed ps20 inhibits the growth of
PC3 human prostate metastatic cell line and enhances protein secretion
by .2-fold (9). Stable ps20-expressing COS-7 cells (transformed sim-
ian ﬁbroblasts) secrete ps20 and are growth inhibited. Additionally,
COS-7 and PC3 cells are growth inhibited by bacterially produced
ps20 (11). Human WFDC1 maps to chromosome 16q24, an area char-
acterized by a frequent loss of heterozygosity in multiple cancers such
as breast, prostate and liver. Watson et al. (12) integrated data from
expression arrays and high-resolution comparative genomic hybridiza-
tion analysis of chromosome 16q derived from 16 prostate tumors and
identiﬁed six genes that were signiﬁcantly downregulated compared
with normal prostate tissue, among which was WFDC1. In contrast,
several studies aiming at deciphering the correlation between cancer
samples that harbor aberrations in chromosome 16 and WFDC1 dis-
covered low mutation rate and no signiﬁcant alteration in WFDC1
expression in various cancers (13–15). Analysis of WFDC1 expression
in prostate cancer using reverse transcription–polymerase chain reac-
tion showed that WFDC1 levels are signiﬁcantly downregulated, but no
mutations were detected in its coding region (16). All the above imply
that WFDC1 is not a classical tumor suppressor but nonetheless can
inhibit cell proliferation.
Abbreviations: CAFs, cancer-associated ﬁbroblasts; cDNA, complementary
DNA; ECM, extracellular matrix; IL, interleukin; mRNA, messenger RNA;
NAF, normal-associated ﬁbroblast; PDL, population doubling; PF, prostate
ﬁbroblast; ps20, prostate-speciﬁc 20; QRT-PCR, quantitative real-time poly-
merase chain reaction; SKY, spectral karyotyping; aSMA, a-smooth muscle
actin; WFDC1, whey acidic protein four-disulﬁde core domain 1.
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neighboring epithelia, we sought to establish an in vitro system of
normal and cancer-associated ﬁbroblasts that will permit the investi-
gation of the phenotypic and genotypic differences between the two,
with an emphasis on genes that might act in a paracrine fashion on the
growth and survival of adjacent epithelia. The comparison between
CAFs and NAFs demonstrated distinct phenotypes. A complementary
DNA (cDNA) microarray analysis allowed us to detect speciﬁc gene
signatures whose expression differed between the two cultures. Fi-
nally, we focused on WFDC1 that exhibited an altered expression
pattern between NAFs and CAFs. In our experiments, we set out to
assess its effect on various cell growth parameters as well as its ex-
pression pattern in various cancer tissues, cell cultures and cell lines.
Materials and methods
Cell culture
Primary human prostate ﬁbroblasts (PFs) (designated PF179; 179, patient number)
were isolated from a prostatectomy specimen, marginal and distal to the prostate
tumor (CAFs and NAFs, respectively). PF179 cell cultures and WI-38 human
embryonic lung ﬁbroblasts were grown in minimum essential medium supple-
mented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate and
antibiotics. Phoenix and HT1080 cell lines were grown in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal calf serum, 2 mM L-glutamine and
antibiotics. Cells were maintained in a humidiﬁed incubator at 37Ca n d5 %C O 2.
Sarcoma samples
RNA samples were isolated from various human sarcoma specimens. Fibro-
sarcomas (ﬁve), liposarcomas (ﬁve), leiomyosarcoma (ﬁve), neuroﬁbrosarco-
ma, dermatoﬁbrosarcoma and rhabdomyosarcoma were kindly provided by Dr
Paul Meltzer (National Institutes of Health, Bethesda).
Plasmids and constructs
The WFDC1 genewas ampliﬁed from PF179-derivedrandom hexamer-primed
cDNA with speciﬁc primers: 5#-GGGAGGAAATGCCTTTAACC-3# and
5#-TGCTTGCCGTTGCTTTACTG-3# using the Phusion DNA polymerase
kit (Stratagene). The polymerase chain reaction product was cloned into
a pGEM-T Easy vector (Promega), restricted with EcoRI (Roche) and subcl-
oned into pBabe-Hygro retroviral vector.
Retroviral infection
See supplementary Materials and methods (available at Carcinogenesis
Online) for details.
Transfections
HT1080 cells were plated at 1.2   105 cells per well in a six-well plate, 24
hours prior to transfection. Cells were transfected with Fugene-HD (Roche),
200 ng expression vector encoding for GFP for estimation of transfection
efﬁciency, 1500 ng of either empty pBabe-Hygro vector as a control or
pBABE-Hygro vector encoding WFDC1 and 300 ng pBlueScript plasmid
(Stratagene)to completethetotal DNAmassto 2 lg. Cellswere thenincubated
for 48 h at 37C and were either collected for RNA extraction or replated for
crystal violet staining at clonal density.
Spectral karyotype analysis
Halfamillioncellswereplatedper10cmplateandallowedtoinitiateproliferation
for 48 h. Then, the medium was replaced and the cells were incubated for addi-
tional 24 h. Next, the cells were incubated with colcemid (0.1 lg/ml) over night,
trypsinized, lysed with hypotonicbuffer and ﬁxedin glacialacetic acid:methanol
(1:4). Further analysis was performed by Dr Irit Bar-Am as described in detail in
the supplementary Materials and methods (available at Carcinogenesis Online).
Isolation of total RNA and quantitative real-time polymerase chain reaction
Total RNA was isolated using the RNAeasy kit (Qiagen), according to the
manufacturer’s protocol. A 2 lg aliquot was reverse transcribed using
MMLV-RT (Bio-RT) and random hexamer primers. Quantitative real-time
polymerase chain reaction (QRT-PCR) was performed on an ABI 7300 in-
strument (Applied Biosystems) using Platinum SYBR Green and qPCR Super-
Mix (Invitrogen). Speciﬁc primersare provided in the supplementary Materials
and methods (available at Carcinogenesis Online).
cDNA microarray
Total RNAwas extracted using Tri-Reagent (MRC) according to the manufac-
turer’s protocol and sent to the MicroArray department (Weizmann institute of
science, Rehovot, Israel). The procedure was done using Affymetrix Human
Genome U133 plus 2.0 microarray.
BrdU incorporation assay
As described previously (17).
Western blot analysis
ThisprocedureisdescribedindetailinthesupplementaryMaterialsandmethods
(available at Carcinogenesis Online).
Growth curves
Cellsweregrownuntilsubconﬂuencedensity,harvestedwithtrypsinandreplatedat
a cell density of 2500 or 1250/cm2. Population doublings (PDLs) at each passage
were calculated using the formula: PDLs 5 log (cell output/cell input)/log 2.
Colony-forming efﬁciency assay
PF179T cells were seeded in triplicates at a cell density of 20/cm2.M e d i u mw a s
replaced every 3–4 days. Twoweeks after plating, cells were stained with crystal
violet and colonies were counted. Additionally, the crystal violet was extracted
with acetic acid and quantiﬁed with a spectrophotometer using a 590 nm ﬁlter.
Contact inhibition assay
PF179T cells were seeded in duplicates at a cell density of 900/cm2 plates.
Mediumwasreplacedevery3–4days.Cells werecollectedandcountedat each
designated time point.
Results
CAFs demonstrate a higher proliferation capacity than NAFs
Primary human PFs (designated PF179) were isolated from a prosta-
tectomy specimen, marginal and distal to the prostate tumor (CAFs
and NAFs, respectively). Since CAFs isolated from malignant tissues
usually demonstrate a distinct phenotype from NAFs, we compared
several proliferation features between the NAFs and the CAFs.
First, both cell cultures were immortalized by infection with a retro-
viralvectorencodingforthehumantelomerasecatalyticsubunit,hTERT
as reported previously (18–21). We compared the growth rate of the
primary and hTERT-immortalized cell cultures by counting and replat-
ing them weekly and calculating their accumulated PDLs. As shown in
Figure 1A, non-immortalized NAFs demonstrated low proliferation
rate, and following 30 PDLs entered a complete growth arrest, whereas
non-immortalized CAFs accumulated 45 PDLs before entering growth
arrest. As expected, both immortalized NAFs and CAFs overcame
growth arrest and continued to divide in culture. However, CAFs
divided twice as fast as NAFs during the examined period with a
P-value of 2.9   10 9 as calculated by Student’s t-test (Figure 1B).
To further substantiate this phenomenon and in order to obtain addi-
tional insights into possible changes in the cell cycle distribution, we
conducted a BrdU incorporation assay that permits an accurate com-
parison of the proportion of cells found at the S-phase of the cell cycle.
As depicted in Figure 1C and supplementary Figure 4 (available at
Carcinogenesis Online), the CAFs population consisted of 15%
BrdU-positive cells in contrast to only 4.3% in the NAFs population,
conﬁrming the replicative advantage of the CAFs. Next, we performed
a contact inhibition assay. Normal cells demonstrate a loss of cell di-
vision due to contact with another cell when optimum size and volume
of the tissue is achieved, whereas abnormal cells continue to divide. As
depicted in Figure 1D, NAFs reached full conﬂuence after 7 days in
cultureand maintainedthesamecellnumberthroughoutthe duration of
the experiment.CAFs,ontheotherhand,continued todivide regardless
of cell density and after 18 days in culture reached a cell number 4-fold
higher than the NAFs. Subsequently, we conducted a colony-forming
efﬁciency assay that measures the ability of the cells to form tightly
packed colonies when seeded at low cell density. As shown in Figure
1E, CAFs formed three times more colonies than the NAFs. All in all,
these experiments suggest that CAFs exhibit a higher proliferative
capacity as compared with NAFs.
Both NAFs and CAFs demonstrate genomic stability
To evaluate whether changes in the proliferation rate observed above
can be attributed to gross genetic changes manifested as chromosomal
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21aberrations, we conducted a spectral karyotyping (SKY) analysis us-
ing condensed DNA from several metaphases from each cell culture.
Nochromosomalaberrationsweredetectedinnoneofthecell cultures
examined (supplementary Figure 1 is available at Carcinogenesis
Online). Based on the SKY data, we concluded that both CAFs, which
lie in close proximity to the tumor and are subjected to its malignant
signals, and NAFs, that are more distal to the tumor, maintained their
chromosomal integrity. Thus, we hypothesize that the pronounced
variations in the proliferation patterns we observed above may stem
from either subtle genetic aberrations or epigenetic alterations that
result in differential gene expression.
CAFs express lower levels of a-smooth muscle actin than NAFs
CAFs are often considered to be ‘activated’ ﬁbroblasts or myoﬁbro-
blasts. Dvorak (22) noted a striking resemblance between many of
the signaling processes occurring in tumor progression and those in-
volved in wound healing. An important hallmark for myoﬁbroblasts in
wound healing as well as in cancer is the expression of differentiation
markers such as calponin, desmin and most commonly a-smooth mus-
cle actin (aSMA) (23–25). However, other studies have shown down-
regulation of the very same markers in prostate cancer-associated
stromal cells (26,27). Because of these rather contradictory data in
the literature, it was important to measure the expression of aSMA
as a representative marker in our cell cultures. The results presented
in supplementary Figure 2A (available at Carcinogenesis Online) in-
dicate a 10-fold decrease in the messenger RNA (mRNA) levels of
aSMA in the CAFs compared with the NAFs, as measured by QRT-
PCR. A comparable decrease in the protein level of aSMA was also
observed using western blot (supplementary Figure 2B is available at
Carcinogenesis Online). To conclude, the basal expression level of
aSMA was signiﬁcantly reduced in the CAFs.
NAFs and CAFs demonstrate a differential gene expression proﬁle
Since NAFs and CAFs exhibit some differences in their biological
behavior and changes in gene expression such as aSMA, we decided
to adopt a genome-wide approach in order to discover speciﬁc expres-
sion signatures that might account for their distinct behavior. To that
end, we performed a global expression proﬁling analysis using cDNA
microarrays on RNA samples obtained from four distinct cell cultures:
immortalized and non-immortalized NAFs and CAFs. Class compari-
son analyses using the BRB-ArrayTools software (28) were performed
on genes that differ in their expression by at least 1.5-fold from the
median expression level in at least one sample. In order to assess the
effectofthehTERTintroductiononthegenesexpression,wecompared
Fig. 1. CAFs demonstrate higher proliferation capacity than NAFs. Primary (A) and hTERT-immortalized (B) NAFs and CAFs were counted and replated weekly
andtheiraccumulated PDLswerecalculatedasdescribed.(C) Cells werelabeledwithBrdU andpropidiumiodideandanalyzedusingﬂowcytometry.Theaverage
proportion of S-phase (BrdU positive) cells is displayed ± standard deviation of three repeats.  Denotes a signiﬁcant increase, P 5 2.2   10 4.( D) Cells were
seeded at identical conﬂuence and were collected and counted at the indicated time points. The graph indicates the mean number of the counted cells ± standard
deviation.  Denotes a signiﬁcant increase, P   1   10 5.( E) Cells were seeded at low density in triplicates, grown for 11 days and then stained with crystal
violet. Plates were scanned, and the average number of colonies was calculated. The graph indicates the mean number of colonies ± standard deviation.  Denotes
a signiﬁcant increase, P 5 9.34   10 7.
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22the immortalized cell cultures with the non-immortalized ones. This
comparison resulted in a list of only three genes (P-value , 0.001),
indicating a mild directional effect of the immortalization on the ex-
amined cell cultures. Next, we analyzed the expression proﬁles using
the same statistical method and thresholds, for altered gene expression
between the NAFs and CAFs. This analysis yielded a list of 161 gene
probes that were divided into two groups: NAFs upregulated genes and
CAFs upregulated genes (Tables I and II, respectively).
In concordance with the notion that the stromal cells affect their
surroundings via the ECM, we used the ‘DAVID Bioinformatics’
software (29) to identify genes that are related to the extracellular
region. After ﬁltration of the microarray data into a list consisting
of the 2000 most differentially expressed genes, we observed a signif-
icant enrichment of extracellular space-related genes (9.32%, P-value
1.6   10 5). These genes were then clustered using the Cluster 3.0
software (30) according to their expression pattern (supplementary
Figure 3A is available at Carcinogenesis Online). To validate the
microarraydata,weconductedQRT-PCRanalysesforarepresentative
number of candidate genes. We have chosen to focus on three genes
from each group that were both ECM related and reported previously
inthe literature as differentially expressed inhuman cancers. From the
CAFs upregulated gene list, we examined interleukin (IL) 13 receptor
a2, Spondin2 and IL7. IL13 receptor a2 is a subunit of the IL13
receptor complex that was shown to be highly expressed in ovarian
cancer specimens when compared to normal ovary samples (31).
Spondin2 is a cell adhesion protein that was identiﬁed as a candidate
marker ofprostate cancer (32). IL7 is a cytokine importantfor B and T
cell development that can be produced by some human tumor cells
and is involved in tumor development and progression (reviewed in
ref. 33). From the NAFs upregulated gene list, we examined Periostin,
matrix metalloproteinase3 and WFDC1. Periostin induces cell attach-
ment and spreading and plays a role in cell adhesion. Its mRNA
expression was shown to be markedly downregulated in a variety of
human cancer cell lines and in human lung and bladder tumors
(34,35). Matrix metalloproteinase3 is an ECM-degrading proteinase
that on the one hand might prompt normal mammary epithelial cells
to disaggregate and undergo epithelial to mesenchymal transition and
become invasive (36) and on the other hand is secreted from senescent
ﬁbroblasts (37). WFDC1 is a secreted growth inhibitor that is known
to be downregulated in the stroma of prostate cancer (16). As depicted
in supplementary Figure 3B (available at Carcinogenesis Online),
we found that the expression levels of the various genes examined
by QRT-PCR agreed with the expression proﬁle seen by the cDNA
microarray analysis.
Due to its ECM localization and relevance to prostate cancer, we
decided to focus our study on WFDC1.
WFDC1 expression level is repressed in highly proliﬁc cell cultures
and in tumors
Since WFDC1 level was signiﬁcantly decreased in CAFs (Table II,
supplementary Figure 3 is available at Carcinogenesis Online), which
isinagreementwithpreviouslypublishedstudiesshowingadecreaseof
its level in prostate reactive stroma (16), we decided to further charac-
terize the expression pattern of WFDC1. First, we examined the gen-
erality of our observation. To that end, we utilized two systems that
Table I. NAFs upregulated genes
Gene symbol Fold
induction
P-value Gene
symbol
Fold
induction
P-value
SERPINB2 33.4 1.1E-04 MME 3.1 8.7E-04
CD200 13.5 2.0E-04 SAMD3 3.0 5.5E-04
WFDC1 12.5 6.4E-05 RGS7 3.0 7.6E-04
JAM2 9.7 4.7E-05 PSG1 3.0 4.8E-04
AFF3 9.5 3.1E-04 PCLO 3.0 5.5E-04
CORIN 9.4 9.6E-06 PRG1 3.0 6.1E-04
LOC339903 8.8 7.0E-05 PCSK7 2.9 3.6E-04
OXTR 7.6 4.8E-05 SESN3 2.9 5.5E-04
FAM84A/
LOC400944
7.3 1.7E-04 C21orf7 2.9 3.8E-04
CCND2 6.6 5.1E-05 FGF1 2.9 8.4E-04
JPH2 6.4 2.4E-04 DDAH1 2.9 5.7E-04
Similar to
yeast ARV 1
6.3 5.6E-04 SCUBE3 2.9 5.6E-04
NRXN3 6.3 5.1E-05 SLC2A1 2.8 9.7E-04
FGL2 6.1 6.3E-04 MAMDC2 2.8 5.3E-04
F2RL2 5.8 2.7E-05 FHL1 2.8 7.1E-04
SCN2A2 4.6 2.3E-04 CXCL6 2.7 7.6E-04
RASGRP2 4.3 1.0E-04 MGC11324 2.5 9.0E-04
INMT 4.3 3.0E-04
OPN3 4.2 3.0E-04
DNAJC6 4.2 4.6E-04
CPXM2 4.1 1.4E-04
DMD 3.9 1.2E-04
PSG7 3.9 5.7E-04
DKFZp761P0423 3.8 1.5E-04
PSG4 3.6 2.5E-04
ITGA6 3.4 7.0E-04
PVR 3.4 6.8E-04
NEDD9 3.3 7.1E-04
PTGDS 3.3 3.8E-04
KRTAP2-1/2-4 3.3 7.1E-04
CLDN1 3.3 6.9E-04
EPHB6 3.2 2.5E-04
KIAA1913 3.2 9.7E-04
CCND1 3.2 8.4E-04
SMTN 3.2 5.2E-04
SYNPO2 3.1 2.4E-04
ANXA3 3.1 2.9E-04
Table II. CAFs upregulated genes
Gene symbol Fold
induction
P-value Gene
symbol
Fold
induction
P-value
IL13Ra2 42.7 6.0E-07 ZFPM2 4.1 4.5E-04
SPON2 35.8 1.6E-06 IGFBP3 4.1 9.3E-04
TNXB 11.8 3.9E-04 SLC19A2 4.0 4.2E-04
NFIB 9.8 3.7E-05 MFAP5 4.0 5.9E-04
GLDN 9.8 1.5E-05 ID4 4.0 4.9E-04
PCOLCE2 9.5 4.8E-06 PCTK2 3.8 3.7E-04
ASB5 8.8 5.7E-05 STEAP1 3.8 3.6E-04
LIMS3 8.5 4.5E-06 SLC27A6 3.7 4.9E-04
GATA3 8.4 6.2E-05 CA12 3.7 5.1E-04
FAM38B 7.3 2.4E-04 EGR3 3.7 1.5E-04
SGCG 6.8 3.9E-04 DOK5 3.5 4.2E-04
MOCOS 6.6 1.2E-05 L1MS1 3.4 4.7E-04
GADD45B 6.3 5.6E-04 SOCS3 3.4 4.0E-04
RCN3 6.2 3.3E-04 KLF9 3.4 3.6E-04
ID2 /// ID2B 6.2 4.0E-05 ALDH1A3 3.4 2.8E-04
KLF10 6.0 9.1E-04 FGF9 3.3 4.8E-04
ACVR2A 6.0 1.4E-05 ANKRD10 3.3 2.0E-04
PEAR1 5.9 1.8E-05 IRF2BP2 3.3 5.2E-04
RFX3 5.6 6.2E-05 CCDC8 3.1 2.9E-04
VIT 5.6 9.7E-05 EYA1 3.1 2.8E-04
FAM49A 5.5 9.8E-04 ARIH1 3.0 4.0E-04
COL14A1 5.3 5.0E-04 MYLIP 3.0 9.6E-04
ZNF521 5.3 1.1E-04 FNBP1L 3.0 6.7E-04
LOC200230 5.1 1.5E-04 CLDN11 2.9 8.0E-04
PDE3B 5.1 3.6E-05 GPC6 2.9 8.3E-04
EBF 5.0 9.5E-04 NFIA 2.9 3.7E-04
AQP3 4.9 3.2E-05 PDE4DIP 2.8 4.2E-04
MBP 4.8 4.6E-04 KCNK1 2.8 8.4E-04
FRAS1 4.7 2.2E-04 B4GALT1 2.8 7.0E-04
INSIG1 4.6 1.5E-04 RBMS1 2.8 7.9E-04
CLEC2B 4.6 9.8E-04 MEIS1 2.7 6.1E-04
SIPA1L2 4.5 1.5E-04 PDE4D 2.7 9.7E-04
IL7 4.5 4.0E-04 SH3D19 2.7 7.8E-04
MN1 4.4 5.2E-05 SPAG9 2.6 8.4E-04
FLRT2 4.4 6.1E-04 CXCL12 2.5 9.0E-04
PBEF1 4.4 2.3E-04 NFKBIZ 2.5 9.6E-04
CRABP2 4.2 6.0E-04
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23were previously established in our lab by immortalization of human
primary mesenchymal cells. In both systems, following a prolonged
culturing period, cells spontaneously acquired an accelerated growth
rate and lost the expression of key tumor suppressors (38,39). The ﬁrst
systemwastheWI-38 lungﬁbroblastsconsisting ofearlyslow-growing
passages (Tslow) and fast-growing passages (Tfast). The second system
was the early (passage 27) and late (passage 107) passages of PM151T
prostate-derived immortalized smooth muscle cells. As expected,
a marked reduction of WFDC1 mRNA level inthe late passage-derived
samples was observed in both systems (Figure 2A). These observations
prompted us to measure the level of WFDC1 in several cell lines of
mesenchymal origin as well as in human sarcomas. We found that
WFDC1 is expressed at low levels in human sarcomas (n 5 18) and
at very low to undetectable levels in the transformed mesenchymal cell
Fig. 2. WFDC1 expression level is repressed in highly proliﬁc cell cultures and in tumors. (A) Basal expression levels of WFDC1 invarious hTERT-immortalized
mesenchymal cells (PF179TNAFs, PM151Tpsg26and WI-38 Tslow) and theirhighly proliﬁc counterparts (PF179TCAFs,PM151Tpsg107 and WI-38Tfast) were
determined by QRT-PCR. The results are presented as a mean ± SD of two duplicate runs from a representative experiment.  Denotes a signiﬁcant decrease of
WFDC1, P   0.02. (B) RNAwas produced from PF179T cell cultures, 18 sarcoma specimens (as described in Materials and Methods) and 3 ﬁbrosarcoma cell
lines: SAOS, U2OS and HT1080. QRT-PCR analysis was conducted for WFDC1 expression. The results are displayed on a logarithmic scale.  Denotes
a signiﬁcant decrease, P , 0.03.   P , 1.2   10 16.( C) The Oncomine database was queried for studies in which WFDC1 expression signiﬁcantly differs
between cancer and normal samples as described in Material and Methods. The P-value designates the probability that the observed difference in WFDC1
expression between normal and cancer samples is due to random chance. The bars represent 25–75% interval of normalized WFDC1 expression levels in each
group. The deviation lines represent 10–90% percentiles and dots represent samples with minimum and maximum expression level in a given group.
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24lines U2OS, HT1080 and SAOS, compared with the PFs (Figure 2B).
To further conﬁrm the hypothesis that WFDC1 repression is a frequent
event during malignant transformation, we searched the ‘Oncomine’
database (40) for clinical tumor sample studies with signiﬁcant
differential expression of WFDC1 compared to their corresponding
normal tissues. We found that WFDC1 was signiﬁcantly decreased
in prostate cancers compared with normal prostate tissues.
Metastatic prostate cancers exhibited even lower levels of WFDC1
expression than prostate adenocarcinomas (41,42). WFDC1 downregu-
lation was also observed in other cancer types, namely, bladder, lung
and brain (43–45) (Figure 2C).
Owing to the correlation between the reduction in WFDC1 mRNA
and cell proliferation rate, we sought to assess the growth-inhibiting
effect of WFDC1 in HT1080 cells, a human ﬁbrosarcoma cell line, in
which WFDC1 is not expressed. To that end, we transfected HT1080
with aretroviralvector containing either the WFDC1 coding sequence
or with an empty vector as a control and examined their colony for-
mation efﬁciency. We found that overexpression of WFDC1 exerted
an inhibitory effect on the colony formation efﬁciency of HT1080
cells (Figure 3). This result is in agreement with the notion that
WFDC1 expression does not only correlate with low proliferation rate
but may also directly inhibit proliferation when introduced exoge-
nously. Moreover, WFDC1 inhibitory function might explain the se-
lective pressure that underlies its downregulation in malignant tissues.
WFDC1 is upregulated during cellular senescence
Cellular senescence was initially described by Hayﬂick (46), as he
pointed out that normal human ﬁbroblasts undergorobustcell division
in tissue culture, followed by a gradual decrease in PDL rate over
time, until they cease to divide altogether. Nonetheless, these cells
remain viable and metabolically active despite their inability to pro-
liferate even in the presence of nutrients and growth factors. Other
than growth arrest, there are no widely speciﬁc markers for cellular
senescence. Senescence-associated b-galactosidase activity is de-
tected by histochemical staining in most senescent cells; however, it
is also induced in dense cell populations and prolonged conﬂuence in
culture. In addition, p16, a known regulator of senescence, which is
expressedbymanybutnotallsenescentcells,isoftenusedasamarker
as well (47). Since WFDC1 expression level was high in slowly di-
viding cells, we set to evaluate its levels in cells undergoing senes-
cence. To that purpose, we used two normal human primary lung
ﬁbroblasts cell types: WI38 and IMR90. IMR90 cells were growth
arrested after 12 PDLs, whereas WI38 ceased to proliferate after 14
PDLs (Figure 4A and C). RNAwas produced from pre-senescent and
senescent cells and the expression levels of p16 and WFDC1 were
measured by QRT-PCR. As expected, p16 was elevated upon senes-
cence (Figure 4B and D). WFDC1 mRNA level was increased as well,
implying yet again on its production by cells with reduced prolifera-
tion rate, and suggesting that WFDC1 level might be considered as
a potential marker for senescent cells.
Discussion
Itiswellacceptedthatmalignanttransformationisgreatlydependenton
thetumorstroma.CAFs,thatconstitutealargeproportionofthecancer-
associated stroma, play a key role in malignant transformation mainly
viatheactivationofECM-relatedgenes(2).Theaimofourstudywasto
further characterize the biological behavior of prostate-derived CAFs
and uncover their possible altered gene expression patterns.
The prostate CAFs studied here exhibited a higher proliferation rate
than their NAFs counterparts, formed more colonies when seeded at
low cell density and were less prone to contact inhibition. SKYanal-
ysis suggested that both CAFs and NAFs maintain their chromosomal
integrity and ploidy. Therefore, the observed variations in the pro-
liferation patterns were probably due to subtle genetic or epigenetic
changes that are non-detectable by SKYanalysis. These results are in
agreement with other studies that showed enhanced production of
collagens, epithelial growth factors and rapid proliferation rate of
CAFs (3–5). Higher proliferation rate possibly grants the CAFs
a long-term advantage over other cell types in the stroma compart-
ment such as NAFs and smooth muscle cells and enables them to
become the predominant cell type in the vicinity of the tumor. Fur-
thermore, factors secreted from the CAFs might accelerate tumor
progression (48). Thus, it might be of great importance for the tumor
cells to favor CAFs growth in the tumor surroundings via reciprocal
interactions. Elucidation of the cellular pathways that govern CAFs
proliferation might serve as a platform to target their growth and that
of their adjacent tumor cells.
DuetosimilaritiesbetweenCAFsandmyoﬁbroblaststhattakepartin
the wound healing process, CAFs are often considered to be activated
ﬁbroblasts or myoﬁbroblasts (22). For example, both are recruited by
platelet-derived growth factor and activated by transforming growth
factor-b (48). Despite these similarities, these processes might last
months and years in the context of cancer, in contrast to a transient
period in the wound healing process. An accepted hallmark for myoﬁ-
broblasts in wound healing as well as in cancer is the expression of
differentiation markers such as calponin, desmin and most commonly
a-SMA (23–25). In contrast, Tuxhorn et al. (26) observed high expres-
sion of aSMA in 95% of the normal prostate stroma compared with
only 37% of the reactive stroma. This study consisted of 84 normal
prostate stroma samples that were compared with 89 samples taken
from stromal cells adjacent to a Gleason 3 tumor. A similar pattern
of expression was observed also with the differentiation marker calpo-
nin. In addition, a study aimed at examining reactive stroma as a pre-
dictor of biochemical-free recurrence in prostate cancer, that was
Fig. 3. OverexpressionofWFDC1in the HT1080celllineinhibitsitsproliferationrate. Cellswere transiently transfectedwitheither a retroviralvector containing
the WFDC1 coding sequence or an empty vector. (A) Cells were tested for WFDC1 expression using QRT-PCR. The results are presented as a mean ± SD of two
duplicate runs from a representative experiment.  Denotes a signiﬁcant increase in WFDC1 expression compared with the control, P   4.6   10 4.( B) Cells
were seeded at a low density, incubated for 4 days and dyed with crystal violet. The crystal violet was removed with acetic acid and quantiﬁed with
a spectrophotometer using a 590 nm ﬁlter (right hand graph). The graph indicates the mean number of three repeats ± standard deviation.  Denotes a signiﬁcant
decrease in OD 590 nm compared with the control, P   1.1   10 4.
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aSMA are hallmarks of cancer-associated reactive stroma, relative to
normal ﬁbromuscular stroma (27). We examinedthe basal level expres-
sion of aSMA in the NAFs and CAFs and found a 10-fold decrease in
the expression of aSMA in the CAFs. Prostate carcinoma cells, espe-
cially those that have progressed into a higher level of malignancy,
secrete transforming growth factor-b and perhaps promote the myoﬁ-
broblasts phenotype in adjacent stroma. The expression level of differ-
entiation markers in the stroma might be dependent on the malignant
stage of the adjacent epithelial cells and may account for the contra-
dictive reports of the differentiation marker levels in CAFs. Owing to
theincreasing controversythatexistsintheliterature,andinlightofour
own ﬁndings, our conclusion is that aSMA cannot serve as a deﬁnitive
general marker of CAFs.
Several studies utilizedgenome-wide expression proﬁling inorder to
characterize the altered gene expression in the prostate reactive stroma,
either on a large cohort of patients specimens or in a exogenously
modiﬁed stroma (49–51). We report here for the ﬁrst time on a cDNA
microarray analysis that compared normal and cancer-associated PFs
from the same patient without exogenous intervention. This approach
was chosen in order to identify speciﬁc gene signatures that might be
altered between closely related cells. Bioinformatical analysis revealed
a list of 161 differentially expressed gene transcripts. Among them, 96
were upregulated in the CAFs compared with 65 in the NAFs. We also
witnessed an enrichment in extracellular-related genes among the dif-
ferentially expressed transcripts, which is in agreement with the notion
that ﬁbroblasts are able to inﬂuence their microenvironment via the
secretion of proteins such as collagens, cytokines and growth factors
(48). Although the exact function of some of these factors and their
contribution to malignancy are not fully understood, their deregulation
is consistent in various cancers. We identiﬁed some novel genes whose
expression differed between NAFs and CAFs that were both ECM
related and previously reported to exhibit a deregulated expression in
cancer. Future studies might utilize the altered gene signatures of the
CAFs to identify possible speciﬁc markers of the reactive stroma.
In our present study, we focused on the altered expression of
WFDC1 that we found to be downregulated in the CAFs. WFDC1
is a member of a family composed primarily of secreted serine
protease inhibitors, that was ﬁrst reported to be secreted from rat mes-
enchymal cells and to act as a growth inhibitor of the PC3 prostatic cell
line in vitro (9). However, WFDC1 might exert its effect in different
manners. In a study conducted by McAlhany et al. (52), WFDC1 was
shown topromote endothelial cell motilitybut did not have an effect on
endothelial cell proliferation. Furthermore, invivo experiments in mice
revealed that WFDC1 causes an elevation in microvascular density of
implanted tumors and an increase in their volume, suggesting that
WFDC1 might facilitate angiogenesis. All in all, these data suggest
that WFDC1 is a multifunctional protein and that its end point effect
dependsonthespeciﬁcityofthecelloritscontext.AlthoughWFDC1is
localized in the human genome to chromosome 16q24, an area of
frequent loss of heterozygosity in multiple cancers (11), and despite
its downregulation in prostate cancer (16), accumulated evidence sup-
port the notion that WFDC1 is not a classical tumor suppressorgene. In
our study, we showed that WFDC1 expression was dramatically down-
regulated during prolonged culturing in two mesenchymal cellular sys-
tems and in CAFs. We also discovered that WFDC1 is signiﬁcantly
downregulated in clinical tumors of mesenchymal origin as well as in
several carcinomas including prostate, bladder, lung and brain and that
prostatemetastasesexhibitevenlower levelof WFDC1expressionthan
primary prostate adenocarcinoma. Overexpression of WFDC1 exerted
an inhibitory effect on the growth rate of HT1080 cells. Furthermore,
we report here for the ﬁrst time that WFDC1 mRNA level is upregu-
lated in ﬁbroblasts undergoing senescence. In conclusion, WFDC1
function is related to the inhibition of cell growth. Although its role
as a tumor suppressor is not established, its absence might serve as a
biomarker for cellular transformation in a tissue/cell-speciﬁc manner.
Supplementary material
Supplementary Materials and methods and Figures 1–4 can be found
at http://carcin.oxfordjournals.org/
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